TY - JOUR
T1 - Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention
T2 - Results From the PARIS Registry
AU - Chandrasekhar, Jaya
AU - Bansilal, Sameer
AU - Baber, Usman
AU - Sartori, Samantha
AU - Aquino, Melissa
AU - Farhan, Serdar
AU - Vogel, Birgit
AU - Faggioni, Michela
AU - Giustino, Gennaro
AU - Ariti, Cono
AU - Colombo, Antonio
AU - Chieffo, Alaide
AU - Kini, Annapoorna
AU - Saporito, Richard
AU - Michael Gibson, C.
AU - Witzenbichler, Bernhard
AU - Cohen, David
AU - Moliterno, David
AU - Stuckey, Thomas
AU - Henry, Timothy
AU - Pocock, Stuart
AU - Dangas, George
AU - Gabriel Steg, P.
AU - Mehran, Roxana
N1 - Publisher Copyright:
© 2016 Wiley Periodicals, Inc.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Background: Proton pump inhibitors (PPI) may decrease the availability of clopidogrel by competitive antagonism, leading to a potential increase in ischemic events. Methods: We evaluated patients from the all-comer PARIS registry treated with dual antiplatelet therapy (DAPT) with aspirin and clopidogrel following coronary stenting for outcomes stratified by PPI use. Two-year major adverse cardiovascular events (MACE), composite of cardiac death, myocardial infarction, definite or probable stent thrombosis or target lesion revascularization (TLR), and net adverse cardiac events (NACE), composite of MACE or Bleeding Academic Research consortium (BARC) type 3 or 5 bleeding were assessed. We also explored associations between PPI use and patterns of 2-year DAPT cessation. Results: The cohort comprised 4635 patients (23% PPI users) with mean age 64.4 ±11.4 years. Two year adjusted risk of MACE (HR: 1.27, 95% CI: 1.04–1.55), NACE (HR: 1.21, 95% CI: 1.01–1.44) and TLR (HR: 1.33, 95% CI: 1.04–1.71) were significantly higher in PPI users vs. non-users, without a difference in bleeding. Although the incidence of 2-year DAPT discontinuation and interruption was similar, DAPT disruption was significantly lower among PPI users vs. non-users (10.0% vs. 14.7%, P <0.0001). Compared to non-PPI users on continued DAPT, disruption was associated with higher MACE in both PPI users (HR: 2.34, 95% CI: 1.38–3.97) and non-users (HR: 1.41, 95% CI: 1.02–1.94) but greater BARC 3,5 bleeding only in non-PPI users (HR: 2.06, 95% CI: 1.21–3.51). Conclusions: In clopidogrel treated PCI patients, the 2-year adjusted risk of MACE and NACE was significantly higher in PPI users driven by higher TLR compared to non-PPI users, without a difference in bleeding. PPI use was associated with lower incidence of DAPT disruption without an increase in disruption related bleeding compared to non-PPI users on DAPT.
AB - Background: Proton pump inhibitors (PPI) may decrease the availability of clopidogrel by competitive antagonism, leading to a potential increase in ischemic events. Methods: We evaluated patients from the all-comer PARIS registry treated with dual antiplatelet therapy (DAPT) with aspirin and clopidogrel following coronary stenting for outcomes stratified by PPI use. Two-year major adverse cardiovascular events (MACE), composite of cardiac death, myocardial infarction, definite or probable stent thrombosis or target lesion revascularization (TLR), and net adverse cardiac events (NACE), composite of MACE or Bleeding Academic Research consortium (BARC) type 3 or 5 bleeding were assessed. We also explored associations between PPI use and patterns of 2-year DAPT cessation. Results: The cohort comprised 4635 patients (23% PPI users) with mean age 64.4 ±11.4 years. Two year adjusted risk of MACE (HR: 1.27, 95% CI: 1.04–1.55), NACE (HR: 1.21, 95% CI: 1.01–1.44) and TLR (HR: 1.33, 95% CI: 1.04–1.71) were significantly higher in PPI users vs. non-users, without a difference in bleeding. Although the incidence of 2-year DAPT discontinuation and interruption was similar, DAPT disruption was significantly lower among PPI users vs. non-users (10.0% vs. 14.7%, P <0.0001). Compared to non-PPI users on continued DAPT, disruption was associated with higher MACE in both PPI users (HR: 2.34, 95% CI: 1.38–3.97) and non-users (HR: 1.41, 95% CI: 1.02–1.94) but greater BARC 3,5 bleeding only in non-PPI users (HR: 2.06, 95% CI: 1.21–3.51). Conclusions: In clopidogrel treated PCI patients, the 2-year adjusted risk of MACE and NACE was significantly higher in PPI users driven by higher TLR compared to non-PPI users, without a difference in bleeding. PPI use was associated with lower incidence of DAPT disruption without an increase in disruption related bleeding compared to non-PPI users on DAPT.
KW - P2Y12 receptor inhibitor
KW - dual antiplatelet therapy cessation
KW - percutaneous coronary intervention
KW - proton pump inhibitor
KW - thienopyridine
UR - http://www.scopus.com/inward/record.url?scp=84988405270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988405270&partnerID=8YFLogxK
U2 - 10.1002/ccd.26716
DO - 10.1002/ccd.26716
M3 - Article
C2 - 27650638
AN - SCOPUS:84988405270
VL - 89
SP - E217-E225
IS - 7
ER -